US 12,110,339 B2
ICOS ligand variant immunomodulatory proteins and uses thereof
Ryan Swanson, Seattle, WA (US); and Michael Kornacker, Seattle, WA (US)
Assigned to Alpine Immune Sciences, Inc., Seattle, WA (US)
Filed by ALPINE IMMUNE SCIENCES, INC., Seattle, WA (US)
Filed on Nov. 24, 2020, as Appl. No. 17/103,807.
Application 17/103,807 is a division of application No. 15/488,409, filed on Apr. 14, 2017, granted, now 10,882,914.
Claims priority of provisional application 62/475,162, filed on Mar. 22, 2017.
Claims priority of provisional application 62/472,568, filed on Mar. 16, 2017.
Claims priority of provisional application 62/410,842, filed on Oct. 20, 2016.
Claims priority of provisional application 62/394,745, filed on Sep. 14, 2016.
Claims priority of provisional application 62/323,608, filed on Apr. 15, 2016.
Prior Publication US 2021/0188995 A1, Jun. 24, 2021
Int. Cl. C07K 14/705 (2006.01); A61K 39/00 (2006.01); A61P 37/06 (2006.01); C07K 16/28 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/2896 (2013.01) [C07K 14/70532 (2013.01); C07K 16/461 (2013.01); C07K 2317/40 (2013.01); C07K 2319/01 (2013.01)] 21 Claims
 
1. A variant ICOS Ligand (ICOSL) polypeptide, comprising one or more amino acid substitutions at one or more positions in an unmodified ICOSL corresponding to position(s) selected from the group consisting of 54, 84, 119, 120, 143, 152, 155, 203, and 207 with reference to the numbering of residues in SEQ ID NO:32, wherein the unmodified ICOSL comprises (i) the sequence of amino acids set forth in SEQ ID NO:32, or (ii) a portion of the sequence of (i) comprising an IgV domain, wherein the IgV domain is amino acids 19-129 of SEQ ID NO:5.